MI-LINEAGE-LOGISTICS
2.11.2021 08:02:13 CET | Business Wire | Pressemeddelelse
Lineage Logistics, LLC (”Lineage” eller ”selskabet”), en førende global udbyder af temperaturstyret industriel REIT og logistikløsninger, meddelte i dag, at de har afsluttet opkøbet af køleopbevaringsafdelingen i Claus Sørensen Gruppen, en anerkendt operatør inden for køleopbevaring i Danmark.
Købet blev først annonceret den 15. juni 2021.
Udvidelsen i Danmark er en afgørende del af Lineages vækstplaner i Norden. Opkøbet giver Lineages globale rækkevidde en vigtig forbindelse til Danmark, som er ved at udvikle sig til et førende europæisk midtpunkt inden for den globale køleopbevaringsforsyningskæde, med luftfragt og søfartsinfrastruktur i verdensklasse.
Virksomhedens nuværende tilstedeværelse i Danmark forstærkes igennem Lineages opkøb af Claus Sørensen og tilføjer betydelige volumener på strategiske lokationer nær danske havne og centre for fødevareproduktion.
”Claus Sørensens relationer og tilgang til forretning vil sætte skub i vores vækstplaner i Norden”, siger Harld Peters, Senior Vice President for Europa hos Lineage. ”Vi ser frem til at arbejde sammen med dem for at betjene vores kunder i hele Europa”.
Claus Sørensen, som har hovedkvarter i Esbjerg, har en kapacitet på næsten en million kubikmeter og 200.000 pallepositioner fordelt på ni lagre og mere end 250 teammedlemmer. Med opkøbet og færdiggørelsen af igangværende byggeri i regionen, vil Lineages samlede fodaftryk i Danmark omfatte 17 lokationer og næsten 300.000 pallepositioner.
Claus Sørensen leverer køleopbevaring til kød og fjerkræ, brød, is, færdigretter, frugt og grønt og mejeriprodukter. Ud over opbevaring leverer virksomheden blæsefrysning, kvalitetskontrol, ordresammensætning og pakning, isproduktion, told og distribution til detailhandel og catering. Claus Sørensen kan fryse 1.800 tons produkter om dagen. Claus Sørensen er som et vigtigt led i den danske fødevare- og drikkevareforsyningskæde gået sammen med sine kunder for at forbedre deres forsyningskædeoperationer, opnå maksimal energiudnyttelse og beskytte miljøet.
”Lineage er stærkt engagerede i både innovation og service, hvilket passer perfekt til vores mangeårige forpligtelse til at være vores kunders foretrukne partner”, siger Jesper Toft Mathiasen, CEO hos Claus Sørensen. ”Vi glæder os til at blive en del af en virksomhed, der deler vores værdier, og til at slå os sammen med Lineages team i regionen for at transformere vores kunders forsyningskæde og hjælpe dem med at få deres forretninger til at vokse”.
Lineage Logistics kom ind på det nordiske marked i 2020. Siden da har virksomheden opkøbt Lundsøe Køl & Frys A/S med kølelagerfaciliteter i Nordjylland og Aarhus, Super Frost Sjælland ApS og Coldstar ApS, udover opkøbet af Claus Sørensen.
Om Lineage Logistics: Lineage Logistics er en førende udbyder af temperaturstyret industriel REIT og logistikløsninger. Firmaet har et globalt netværk på over 400 strategisk placerede faciliteter med en samlet kapacitet på over 60 millioner kubikmeter, der spænder over 19 lande fra Nordamerika, Europa og Asien-Stillehavsområdet. Lineages ekspertise indenfor brugsklare løsninger, deres uovertrufne netværk af fast ejendom og udvikling af innovativ teknologi er med til at øge distributionseffektiviteten, fremme bæredygtighed, minimere spild i forsyningskæden og, vigtigst af alt, som visionær partner med Feeding America, være med til at brødføde verden. Som en anerkendelse af firmaets initiativer inden for innovation og bæredygtighed opnåede Lineage at blive nr. 17 på CNBC Disruptor 50-listen i 2021, nr. 1 som bedste datavidenskabsvirksomhed og samlet nr. 23 på Fast Companys liste over verdens mest innovative virksomheder i 2019, udover at være med på Fortunes Change The World-liste i 2020. (www.lineagelogistics.com )
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20211102005519/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum